Düsseldorf, North Rhine-Westphalia, Germany
Global CEO and Non-Executive Director with over 25 years of experience driving transformation and sustainable growth in the healthcare and pharmaceutical sectors. Proven record of delivering financial turnarounds and tripling enterprise value during tenure as CEO while enhancing R&D productivity and embedding high-performance cultures across complex global organizations. Recognized for strategic foresight, corporate governance excellence, and effective execution in M&A. Significant experience in portfolio expansion capital market transactions including successfully raising funds and issuing bonds to finance long-term growth. Combines operational rigor with visionary thinking to deliver enduring enterprise value in both executive and board capacities. Open, courageous and engaging personality with an ability to manage a transformational agenda with a clear vision. Uncompromised personal and work ethic.
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern. It has an outstanding pipeline of highly innovative assets in in Fabry Disease, Psoriasis, MS , Systemic Lupus, suspected acute MI, resistant hypertension (TRYVIO). Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).
DKSH is a leading Market Expansion Services provider with a focus on Asia, generating around 12 billion Swiss francs in annual revenue and supporting companies through distribution, marketing, and business development across 30 markets. • Member of the Nomination & Compensation Committee (NCC) and the Merger & Acquisition (MA) Subcommittee DKSH Holding AG is primarily listed on the SIX Swiss Exchange under the ticker symbol DKSH
Grünenthal is a privately owned, science-based global pharmaceutical company headquartered in Aachen, Germany, focused on pain management and related diseases. The company develops and commercializes innovative treatments addressing significant unmet medical needs, with a commercial presence across multiple regions worldwide. In FY2024, Grünenthal reported €1.8 billion in revenue and employs around 4,400 people globally. In recent years, the company has invested more than €2 billion in the acquisition of established brands, successfully integrating them to further strengthen its portfolio and international footprint. Grünenthal is guided by its vision of a “World Free of Pain”, combining innovation, strategic growth, and responsible business practices.
Managing an organization of over 3000 employes (including Operation, R&D, Commercial) and full accountability of P&L , sales >3bn USD. Moved from #12 to #8 in the Market
Member of the European, Middle East and African Senior Leadership Team, developing transformational strategy for a region of >10bn$ - main focus is on shaping new Organizational Design, Business Development, New Commercial Models and Market Access.